Objective To provide a theoretical basis for the treatment of endometrial cancer by comparing the mRNA and protein expression levels of CXCL12 and CXCR4 in endometrial carcinoma. Methods A total of 100 patients admitted to the department from June 2014 to June 2017 were selected as the study subjects. Patients were at the age of 29-77 years, mean age(56. 8±9. 8) years. The expression of CXCL12 and CXCR4 was detected by tissue microarray, im-munohistochemistry and RT-PCR. Observed and recorded the patient's name, age and other basic information, recorded patient treatment efficacy. Results The positive expression rate of CXCL12 in endometrium group was 76. 8％, which was significantly higher than that in atypical endometrial hyperplasia group, simple endometrial hyperplasia group and normal endometrium group whose positive expression rates of CXCL12 were 18. 8％, 50. 0％, 35. 7％ respectively, the differences were statistically significant(P＜0. 05). The positive expression rate of CXCR4 in endometrium group was 71. 4％, which was significantly higher than that in atypical endometrial hyperplasia group, simple endometrial hyperplasia group and normal endometrium group whose positive expression rates of CXCR4 were 56. 3％、42. 9％、28. 6％ respectively, the differences were statistically significant^O. OS). The expression levels of CXCL12 mRNA were (0. 587± 0. 022) and (1. 132±0. 041) in the normal endometrium group and the endometrial carcinoma group respectively(P＜0. 05). The expression levels of CXCR4 mRNA were (0. 253±0. 035) and (0. 522±0. 258) in the normal endometrium group and endometrial cancer group respectively, and the difference was statistically significant (P＜0. 05). The expression of CX-CL12 was not related to the clinical stage and age of the tumor, and the difference was not statistically significant(P＞ 0. 05). The expression of CXCR4 was closely related to the clinical stage of tumor, and the difference was statistically significant (P＜0. 05). Conclusion The expression of CXCL12 and CXCR4 in patients with endometrial carcinoma was significantly increased. The expression of CXCR4 was closely related to the clinical stage of the tumor which provided accurate timing for the treatment of patients with endometrial cancer. At the same time, the majority of medical staff accumulated abundant experience from and these indicators can be widely applied.%目的 通过对比分析趋化因子CXCL12及CXCR4在子宫内膜癌组织中mRNA及蛋白表达水平,为治疗子宫内膜癌提供理论依据.方法 选取自2014年6月～2017年6月本科室接诊的100例患者为研究对象.患者年龄为29～77岁,平均(56.8±9.8)岁.应用组织芯片技术、免疫组化法和RT-PCR法检测患者CXCL12和CXCR4表达水平.观察记录患者的姓名、年龄等基本信息,记录患者趋化因子CXCL12及CXCR4表达水平等指标.结果 CXCL12在子宫内膜癌组患者体内阳性表达率76.8％,明显高于不典型内膜增生组、单纯性内膜增生组和正常内膜组患者阳性表达率18.8％、50.0％、35.7％,差异有统计学意义(P＜0.05);CXCR4在子宫内膜癌组患者体内阳性表达率71.4％,明显高于不典型内膜增生组、单纯性内膜增生组和正常内膜组患者阳性表达率56.3％、42.9％、28.6％,差异有统计学意义(P＜0.05);CXCL12 mRNA在正常内膜组和子宫内膜癌组患者体内表达水平分别为(0.587±0.022)、(1.132±0.041),差异有统计学意义(P＜0.05);CXCR4 mRAN在正常内膜组和子宫内膜癌组患者体内表达水平分别为(0.253±0.035)、(0.522±0.258),差异有统计学意义(P＜0.05).CXCL12表达与患者的肿瘤临床分期、年龄等无关,差异无统计学意义(P＞0.05),CXCR4的表达与患者的肿瘤临床分期密切相关,差异有统计学意义(P＜0.05).结论 CXCL12及CXCR4在子宫内膜癌患者体内表达水平明显升高,CXCR4表达与患者肿瘤临床分期密切相关,为子宫内膜癌患者提供准确的治疗时机,同时,为广大医护人员积累了经验,值得临床广泛推广和应用.
展开▼
